Abstracts tagged "Vasculitis"

Abstract Number: 2638 • 2019 ACR/ARP Annual Meeting
The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis
Irena Doubelt¹, David Cuthbertson ², Gunnar Tomasson ³, Simon Carette ¹, Nader A. Khalidi ⁴, Curry L. Koening ⁵, Carol Langford ⁶, Carol A. McAlear ⁷, Larry W. Moreland ⁸, Paul Monach ⁹, Philip Seo ¹⁰, Ulrich Specks ¹¹, Antoine Sreih ¹², Kalen Young ¹³, Steven Ytterberg ¹¹, Peter A. Merkel ¹⁴, Christian Pagnoux ¹ and VCRC Vasculitis Clinical Research Consortium ¹⁵, ¹Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ²University of South Florida, Tampa, FL, ³Faculty of Medicine, University of Iceland and Landpitali University Hospital, Reykjavik, Iceland, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Utah Hospital, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Johns Hopkins Medicine, Baltimore, MD, ¹¹Mayo Clinic College of Medicine, Rochester, MN, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Vasculitis Foundation, Kansas City, MO, ¹⁴Univeristy of Pennsylvania, Philadelphia, PA, ¹⁵University of Pennsylvania, Division of Rheumatology, philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma and other manifestations of vasculitis, some of which can be life-threatening, cause major organ damage,…
Abstract Number: 966 • 2019 ACR/ARP Annual Meeting
Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients
Laura van Dam¹, Jelle Oskam ², Sylvia Kamerling ², Eline Arends ², Edwin Bredewold ², Magda Berkowska ², Jacques van Dongen ², Ton Rabelink ², Cees van Kooten ² and Onno Teng ², ¹LUMC, Leiden, Zuid-Holland, Netherlands, ²LUMC, Leiden, Netherlands
Background/Purpose: Background: B-cell depletion with rituximab (RTX) is an effective treatment for ANCA-associated vasculitis (AAV) patients. Repeated RTX upon B-cell repopulation or return of ANCAs…
Abstract Number: 1712 • 2019 ACR/ARP Annual Meeting
Head and Neck Involvement of IgA Vasculitis: A Case-Control Study
Michel Villatoro-Villar¹, David Wetter ¹, Cynthia Crowson ², Kenneth Warrington ¹ and Matthew Koster ¹, ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic Rochester, Rochester
Background/Purpose: IgA vasculitis (IgAV) is an immune-complex mediated, small-vessel vasculitis which predominantly involves the skin on the lower extremities. Head and neck involvement is rarely…
Abstract Number: 2641 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Jason Springer¹, Tanaz Kermani ², Antoine Sreih ³, Dianne Shaw ⁴, Kalen Young ⁵, Cristina Burroughs ⁶ and Peter Merkel ³, ¹Kansas University Medical Center, Kansas, MO, ²University of California Los Angeles, Los Angeles, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Vasculitis Foundation, North Carolina, ⁵Vasculitis Foundation, Kansas City, MO, ⁶University of South Florida, Tampa, FL
Background/Purpose: To provide a feasible and sustainable platform for conducting patient-centered research in vasculitis, a prospective, international, internet-based registry of patients with vasculitis has been…
Abstract Number: 970 • 2019 ACR/ARP Annual Meeting
New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction
Emilie Chan¹, Susan Hartzell ², Lisa Anderson ², Chiara Cantarelli ², Chiara Guglielmo ², Ioannis Tassiulas ³, Sofia Andrighetto ², Andrea Angeletti ⁴, Joaquin Manrique Escola ⁵ and Paolo Cravedi ², ¹Mount Sinai Hospital, New York, NY, ²Mount Sinai Hospital, New York, ³Icahn School of Medicine, New York, ⁴Sant'Orsola-Malpighi Hospital, Bologna, Italy, ⁵Complejo Hospital de Navarra, Pamplona, Spain
Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by the production of auto-antibodies and can be treated with rituximab, a B cell-depleting agent. Despite this, limited data…
Abstract Number: 1713 • 2019 ACR/ARP Annual Meeting
Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase
CAMILLE RASMUSSEN¹, MYLENE TISSEYRE ², JULIE GARON-CZMIL ², MARINA ATZENHOFFER ³, Loïc Guillevin ⁴, LAURENT CHOUCHANA ² and Benjamin Terrier ⁴, ¹Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, PARIS, PARIS, France, ²PHARMACOVIGILANCE, COCHIN HOSPITAL, PARIS, PARIS, France, ³PHARMACOVIGILANCE CENTER LYON, FRANCE, LYON, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: IgA vasculitis (IgAV) is an immune complex small-vessel vasculitis, with IgA1-dominant immune deposits. Drug-induced IgAV were rarely reported in the literature, but no systematic…
Abstract Number: 2689 • 2019 ACR/ARP Annual Meeting
GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis
Maria C. Cid¹, Rohan Gandhi ², Marc Corbera-Bellalta ³, Nekane Terrades-Garcia ³, Sujatha Muralidharan ⁴ and John F Paolini ⁵, ¹Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ²Kiniksa Pharmaceuticals Corp., san diego, CA, ³Vasculitis Research Unit, Department of Autoimmune Diseases, University of Barcelona, Barcelona, Spain, ⁴Kiniksa Pharmaceuticals Corp., lexington, MA, ⁵Kiniksa Pharmaceuticals Corp, lexington, MA
Background/Purpose: Giant Cell Arteritis (GCA) is a type of large vessel vasculitis that can cause blindness and aortic aneurysms. A significant unmet medical need remains…
Abstract Number: 1089 • 2019 ACR/ARP Annual Meeting
Causes of Death in ANCA-Associated Vasculitis According to ANCA Type
Zachary Wallace¹, Xiaoqing Fu ¹, Tyler Harkness ¹, John Stone ², Yuqing Zhang ³ and Hyon K. Choi ³, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Survival has improved in ANCA-associated vasculitis (AAV) with evolving management strategies, but patients remain at an increased risk of death compared to the general…
Abstract Number: 1718 • 2019 ACR/ARP Annual Meeting
Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017
Alicia Rodriguez-Pla¹, ¹University of Arizona/Banner Health Medical Center, Tucson, AZ
Background/Purpose: Earlier diagnosis and less toxic immunosuppressive therapies have improved the survival of patients with vasculitis. Current data on mortality rates of vasculitis are limited.…
Abstract Number: 2790 • 2019 ACR/ARP Annual Meeting
Platelet Mediates Neutrophil Extracellular Traps Formation via TLR Signaling in ANCA-associated Vasculitis
Kotaro Matsumoto¹, Hidekata Yasuoka ², Katsuya Suzuki ¹ and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine, Shinjuku-ku, Aichi, Japan
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an autoimmune disease that affects small- to medium-sized blood vessels and causes vascular inflammation and multiple organ…
Abstract Number: 1664 • 2019 ACR/ARP Annual Meeting
Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial
Pierre Charles¹, Agnes Dechartres ², Benjamin Terrier ³, Pascal Cohen ³, Stanislas Faguer ⁴, Antoine Huart ⁴, Mohamed Hamidou ⁵, Christian Agard ⁵, Bernard Bonnotte ⁶, Maxime Samson ⁷, Alexandre Karras ⁸, Noémie Jourde-Chiche ⁹, François Lifermann ¹⁰, Pierre Gobert ¹¹, Catherine Hanrotel-Saliou ¹², Pascal Godmer ¹³, Nicolas Martin-Silva ¹⁴, Grégory Pugnet ¹⁵, Marie Matignon ¹⁶, Olivier Aumaitre ¹⁷, Jean-François Viallard ¹⁸, François Maurier ¹⁹, Nadine Meaux Ruault ²⁰, Sophie Rivière ²¹, Jean Sibilia ²², Xavier Puéchal for the French Vasculitis Study Group ³, Luc Mouthon ³ and Loic Guillevin ³, ¹Institut Mutualiste Montsouris, Paris, France, ²APHP, Paris, France, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁴CHU Toulouse, Toulouse, France, ⁵CHU Nantes, Nantes, France, ⁶Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ⁷CHU Dijon, Dijon, France, ⁸Paris HEGP, Paris, France, ⁹APHM, Marseille, Marseille, France, ¹⁰CH Dax, Dax, France, ¹¹CH Avignon, Avignon, France, ¹²CHU Brest, Brest, France, ¹³CH Bretagne-Atlantique, Vannes, France, ¹⁴CHU Caen, Caen, France, ¹⁵CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹⁶APHP, Créteil, France, ¹⁷CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁸CHU Bordeaux, Bordeaux, France, ¹⁹Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, ²⁰CHU Besançon, Besançon, France, ²¹CHU Montpellier, Montpellier, France, ²²CHU Strasbourg, Strasbourg, France
Background/Purpose: Rituximab (RTX) superiority over azathioprine to maintain ANCA-associated vasculitis (AAV) remission was demonstrated.The MAINRITSAN2 trial was designed to compare an individually tailored RTX-infusion schedule…
Abstract Number: 1722 • 2019 ACR/ARP Annual Meeting
Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy
Peter Gorevic¹, Frank Eng ², Andrea Branch ³, Ahmed Elshamy ⁴, Erin Doyle ² and Thomas Schiano ², ¹Mount Sinai Hospital, New York, ²Mount Sinai Medical Center, New York, ³Mount Sinai Medical School, New York, ⁴California Northstate University, Sacramento
Background/Purpose: BACKGROUND. Mixed Cryoglobulins (MCs) are cold precipitable Rheumatoid Factors (RFs) that provide a biomarker for immune complex formation, particularly associated with chronic Hepatitis C…
Abstract Number: 2791 • 2019 ACR/ARP Annual Meeting
Treatment Response Criteria for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-vasculitis: Results of a Scoping Review
Sara Monti¹, Kaitlin Quinn ², Robin Christensen ³, Alfred Mahr ⁴, Christian Pagnoux ⁵, Carol Langford ⁶, David Jayne ⁷, Peter Merkel ⁸ and Gunnar Tomasson ⁹, ¹University of Pavia, Pavia, Italy, ²Georgetown University Hospital/National Institutes of Health, Washington, DC, ³Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital & Department of Rheumatology, Institute of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark, ⁴Hospital Saint-Louis, University Paris Diderot, Paris, France, ⁵Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁶Cleveland Clinic, Cleveland, OH, ⁷Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Faculty of Medicine, University of Iceland and Landpitali University Hospital, Reykjavik, Iceland
Background/Purpose: A comprehensive assessment of outcome measures to assess response to treatment in ANCA-associated vasculitis (AAV) is necessary to implement.Methods: We performed a scoping review…
Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…
Abstract Number: 1745 • 2019 ACR/ARP Annual Meeting
Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial
Camilla Astley¹, Gleice Clemente ², Maria Teresa Terreri ³, Camila Carneiro ⁴, Marcos lima ⁴, Carlos Buchpiguel ⁴, Hilton Leão Filho ⁴, Fernanda Lima ¹, Ana Lúcia Sá-Pinto ¹, Clovis Silva ⁵, Nadia Aikawa ⁶, Saulo Gil ¹, Hamilton Roschel ¹, Rosa Pereira ⁷ and Bruno Gualano ¹, ¹Division of Rheumatology, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, sao paulo, Sao Paulo, Brazil, ²ivision of Paediatric Rheumatology, Departament of Paediatrics, Universidade Federal de São Paulo, sao paulo, Sao Paulo, Brazil, ³Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Nuclear Medicine Institute, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, sao paulo, Sao Paulo, Brazil, ⁵Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁷Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Childhood-onset Takayasu Arteritis (c-TA) is a rare primary systemic vasculitis that affects aorta and its major branches. This condition is associated with reduced wall…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].